title: Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice.
abstract: The effects of schisandrin B (Sch B) on liver and serum lipid contents were investigated in mice with experimentally-induced hypercholesterolaemia. Hypercholesterolaemia was induced either by oral administration of a cholesterol/bile salts mixture (2/0.5 g kg(-1)) for four days or by feeding a high fat/cholesterol/bile salts (10/1/0.3%, w/w) diet for seven days. Daily co-administration of Sch B (50-200 mg kg(-1), i.g.) for four or six days, respectively, decreased hepatic total cholesterol (TC) and triglyceride (TG) levels (by up to 50% and 52%, respectively) in hypercholesterolaemic mice. Sch B treatment also increased hepatic indices (14-84%) in hypercholesterolaemic mice. The results indicated that Sch B treatment could decrease hepatic TC and TG levels, and increase liver weight, in mouse models of hypercholesterolaemia. Fenofibrate treatment (100 mg kg(-1)) produced effects similar to those of Sch B on the hepatic index and lipid levels of hypercholesterolaemic mice.
authors.affiliation: Department of Pharmacology, Beijing University of Chinese Medicine, Beijing 100102, China. siyuan-pan@163.com
authors.forename: Si-Yuan
authors.initials: SY
authors.lastname: Pan
authors.forename: Hang
authors.initials: H
authors.lastname: Dong
authors.forename: Xing-Ye
authors.initials: XY
authors.lastname: Zhao
authors.forename: Chun-Jing
authors.initials: CJ
authors.lastname: Xiang
authors.forename: Hai-Yan
authors.initials: HY
authors.lastname: Fang
authors.forename: Wang-Fun
authors.initials: WF
authors.lastname: Fong
authors.forename: Zhi-Ling
authors.initials: ZL
authors.lastname: Yu
authors.forename: Kam-Ming
authors.initials: KM
authors.lastname: Ko
mesh_terms: D000818:Animals; D001647:Bile Acids and Salts / Q000633:toxicity; D002784:Cholesterol / Q000378:metabolism; D002791:Cholesterol, Dietary / Q000633:toxicity; D034242:Cyclooctanes / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005234:Fatty Liver / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D011345:Fenofibrate / Q000494:pharmacology; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000302:isolation & purification / Q000494:pharmacology*; D017705:Lignans / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D011083:Polycyclic Compounds / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D032141:Schisandra / Q000737:chemistry*; D014280:Triglycerides / Q000378:metabolism
chemical_list: D001647:Bile Acids and Salts; D002791:Cholesterol, Dietary; D034242:Cyclooctanes; D000960:Hypolipidemic Agents; D017705:Lignans; D011083:Polycyclic Compounds; D014280:Triglycerides; C015499:schizandrin B; D002784:Cholesterol; D011345:Fenofibrate